이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Clearside Biomedical 관리

관리 기준 확인 2/4

Clearside Biomedical's CEO는 George Lasezkay, Apr2019 에 임명되었습니다 의 임기는 5.17 년입니다. 총 연간 보상은 $ 1.54M, 35.6% 로 구성됩니다. 35.6% 급여 및 64.4% 보너스(회사 주식 및 옵션 포함). 는 € 398.95K 가치에 해당하는 회사 주식의 0.51% 직접 소유합니다. 398.95K. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 5 년입니다.

주요 정보

George Lasezkay

최고 경영자

US$1.5m

총 보상

CEO 급여 비율	35.6%
CEO 임기	5.4yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	2.1yrs
이사회 평균 재임 기간	5.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

George Lasezkay 의 보수는 Clearside Biomedical 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$33m
Mar 31 2024	n/a	n/a	-US$35m
Dec 31 2023	US$2m	US$547k	-US$32m
Sep 30 2023	n/a	n/a	-US$37m
Jun 30 2023	n/a	n/a	-US$36m
Mar 31 2023	n/a	n/a	-US$35m
Dec 31 2022	US$2m	US$532k	-US$33m
Sep 30 2022	n/a	n/a	-US$5m
Jun 30 2022	n/a	n/a	-US$2m
Mar 31 2022	n/a	n/a	US$83k
Dec 31 2021	US$2m	US$516k	US$376k
Sep 30 2021	n/a	n/a	-US$25m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$1m	US$503k	-US$18m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	n/a	n/a	-US$18m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$1m	US$385k	-US$31m
Sep 30 2019	n/a	n/a	-US$49m
Jun 30 2019	n/a	n/a	-US$67m
Mar 31 2019	n/a	n/a	-US$82m
Dec 31 2018	US$150k	n/a	-US$83m
Sep 30 2018	n/a	n/a	-US$78m
Jun 30 2018	n/a	n/a	-US$72m
Mar 31 2018	n/a	n/a	-US$65m
Dec 31 2017	US$167k	n/a	-US$59m

보상 대 시장: George 의 총 보상 ($USD 1.54M )은 German 시장( $USD 434.78K ).

보상과 수익: 회사가 수익성이 없는 동안 George 의 보상이 증가했습니다.

CEO

George Lasezkay (72 yo)

5.4yrs

테뉴어

US$1,538,627

보상

Dr. George M. Lasezkay, Pharm D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since March 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive Of...

리더십 팀

이름	위치	테뉴어	보상	소유권
George Lasezkay	President	5.4yrs	US$1.54m	0.51% $ 449.2k
Charles Deignan	Chief Financial Officer	12.7yrs	US$854.41k	0.45% $ 396.0k
Jenny Kobin	Head of Investor Relations	no data	데이터 없음	데이터 없음
Rick McElheny	Senior Vice President of Corporate Development & Alliance Management	2yrs	데이터 없음	데이터 없음
Rafael Andino	Senior Vice President of Engineering & Manufacturing	1.7yrs	데이터 없음	데이터 없음
Susan Coultas	Chief Clinical Officer	2.3yrs	데이터 없음	데이터 없음
Ngai Hang Chong	Chief Medical Officer	less than a year	데이터 없음	0.085% $ 74.5k
Leslie Zacks	Secretary	no data	데이터 없음	데이터 없음

2.1yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: CLM 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
George Lasezkay	President	7.1yrs	US$1.54m	0.51% $ 449.2k
Christy Shaffer	Independent Director	12.7yrs	US$86.08k	0.0059% $ 5.2k
Benjamin Yerxa	Independent Director	2.5yrs	US$88.58k	0.024% $ 21.1k
Jeffrey Edwards	Independent Director	6yrs	US$88.58k	0% $ 0
Clay Thorp	Independent Chair of the Board	12.7yrs	US$96.08k	0.054% $ 47.5k
Carl Regillo	Member of Scientific Advisory Board	4.4yrs	데이터 없음	데이터 없음
William Humphries	Independent Director	12.7yrs	US$91.71k	0.068% $ 59.9k
David Boyer	Member of Scientific Advisory Board	4.4yrs	데이터 없음	데이터 없음
Nancy Hutson	Independent Director	4.4yrs	US$85.46k	0.12% $ 109.1k
Richard Croarkin	Independent Director	8.6yrs	US$91.08k	0% $ 0
Arshad Khanani	Member of Scientific Advisory Board	1.4yrs	데이터 없음	데이터 없음
David Brown	Member of Scientific Advisory Board	4.4yrs	데이터 없음	데이터 없음

5.2yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 이사회: CLM 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.

Clearside Biomedical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought €122k worth of stock

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

High number of new directors

Recent updates

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.15 loss in 1Q 2023)

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought €122k worth of stock

New minor risk - Market cap size

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Third quarter 2023 earnings released: US$0.15 loss per share (vs US$0.13 loss in 3Q 2022)

New major risk - Negative shareholders equity

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.13 loss in 1Q 2022)

High number of new directors

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologic Effect in Oasis Phase 1/2A Clinical Trial of Suprachoroidal CLS-AX (axitinib Injectable Suspension) in Wet AMD Patients

Clearside Biomedical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

High number of new directors

Clearside Biomedical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Clearside Biomedical Completes Dosing in Oasis Phase 1/2A Clinical Trial of CLS-AX in Wet AMD Patients

Clearside Biomedical, Inc. Appoints Susan Coultas as Chief Clinical Officer

First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.13 loss in 1Q 2021)

High number of new directors

Clearside Biomedical, Inc., Annual General Meeting, Jun 22, 2022

Bausch + Lomb and Clearside Biomedical, Inc. Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

High number of new directors

Clearside Biomedical, Inc. Appoints Benjamin R. Yerxa to Its Board of Directors

Clearside Biomedical, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference

High number of new and inexperienced directors

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2020)

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Bausch Health and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE (Triamcinolone Acetonide Suprachoroidal Injectable Suspension)

First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.065 loss in 1Q 2020)

Clearside Biomedical, Inc. Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis

Full year 2020 earnings released: US$0.39 loss per share (vs US$0.81 loss in FY 2019)

Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (Axitinib Injectable Suspension) for the Treatment of Wet AMD

Clearside Biomedical, Inc. to Report Q4, 2020 Results on Mar 10, 2021

New 90-day high: €3.41

Clearside Biomedical, Inc.(NasdaqGM:CLSD) dropped from Russell 2000 Dynamic Index

New 90-day high: €3.35

Clearside Biomedical, Inc. Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

New 90-day high: €2.47

Insider recently bought €82k worth of stock

Insider recently bought €87k worth of stock

Insider recently bought €86k worth of stock

New 90-day high: €1.54

Insider recently bought €89k worth of stock